DE60132702D1 - Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen - Google Patents
Heterozyklische verbindungen als inhibitoren von tyrosin-kinasenInfo
- Publication number
- DE60132702D1 DE60132702D1 DE60132702T DE60132702T DE60132702D1 DE 60132702 D1 DE60132702 D1 DE 60132702D1 DE 60132702 T DE60132702 T DE 60132702T DE 60132702 T DE60132702 T DE 60132702T DE 60132702 D1 DE60132702 D1 DE 60132702D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- inhibitors
- useful
- tyrosine kinases
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22472400P | 2000-08-11 | 2000-08-11 | |
US224724P | 2000-08-11 | ||
PCT/US2001/024390 WO2002014319A2 (en) | 2000-08-11 | 2001-08-02 | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60132702D1 true DE60132702D1 (de) | 2008-03-20 |
DE60132702T2 DE60132702T2 (de) | 2009-03-19 |
Family
ID=22841899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60132702T Expired - Lifetime DE60132702T2 (de) | 2000-08-11 | 2001-08-02 | Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen |
Country Status (9)
Country | Link |
---|---|
US (2) | US6489328B2 (de) |
EP (1) | EP1309596B1 (de) |
JP (1) | JP5000068B2 (de) |
AT (1) | ATE385498T1 (de) |
CA (1) | CA2417635C (de) |
DE (1) | DE60132702T2 (de) |
ES (1) | ES2299501T3 (de) |
MX (1) | MXPA03001306A (de) |
WO (1) | WO2002014319A2 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003257094A1 (en) * | 2002-08-08 | 2004-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
US7135484B2 (en) | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
CA2495589A1 (en) * | 2002-08-14 | 2004-02-26 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
KR20110050745A (ko) * | 2002-10-03 | 2011-05-16 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
RS20050944A (en) | 2003-05-22 | 2008-06-05 | Nerviano Medical Sciences S.R.L., | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
NZ551027A (en) * | 2004-04-08 | 2011-01-28 | Targegen Inc | Benzotriazine inhibitors of kinases |
AU2005276974B2 (en) | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
MX2007011234A (es) | 2005-03-14 | 2007-11-12 | Transtech Pharma Inc | Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa. |
US20080188483A1 (en) * | 2005-03-15 | 2008-08-07 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
JP2009513563A (ja) * | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
NZ563984A (en) * | 2005-06-08 | 2011-11-25 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
EP1951684B1 (de) | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Biarylmetapyrimidinkinaseinhibitoren |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
WO2008063668A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
AU2011333346A1 (en) * | 2010-11-28 | 2013-05-30 | Mapi Pharma Ltd. | Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium |
RU2652638C2 (ru) | 2010-12-17 | 2018-04-28 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы |
KR101934651B1 (ko) * | 2017-10-19 | 2019-01-02 | 가톨릭대학교 산학협력단 | 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR65025B (en) | 1977-07-21 | 1980-06-16 | Thomae Gmbh Dr K | Method for the preparation of new imidazo-isokinolin-diones |
DE3855327D1 (de) | 1987-12-30 | 1996-07-04 | Orion Yhtymae Oy | Heterocyclische Verbindungen |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1998028281A1 (en) * | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
CA2291750A1 (en) | 1997-05-28 | 1998-12-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
ES2256969T3 (es) * | 1997-11-10 | 2006-07-16 | Bristol-Myers Squibb Company | Compuestos de benzotiazol inhibidores de proteina tirosina qauinasa. |
-
2001
- 2001-08-02 MX MXPA03001306A patent/MXPA03001306A/es unknown
- 2001-08-02 JP JP2002519459A patent/JP5000068B2/ja not_active Expired - Fee Related
- 2001-08-02 EP EP01957425A patent/EP1309596B1/de not_active Expired - Lifetime
- 2001-08-02 ES ES01957425T patent/ES2299501T3/es not_active Expired - Lifetime
- 2001-08-02 WO PCT/US2001/024390 patent/WO2002014319A2/en active IP Right Grant
- 2001-08-02 AT AT01957425T patent/ATE385498T1/de active
- 2001-08-02 DE DE60132702T patent/DE60132702T2/de not_active Expired - Lifetime
- 2001-08-02 CA CA002417635A patent/CA2417635C/en not_active Expired - Fee Related
- 2001-08-02 US US09/921,510 patent/US6489328B2/en not_active Expired - Lifetime
-
2002
- 2002-10-15 US US10/271,222 patent/US6844435B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20020119975A1 (en) | 2002-08-29 |
EP1309596B1 (de) | 2008-02-06 |
WO2002014319A2 (en) | 2002-02-21 |
JP5000068B2 (ja) | 2012-08-15 |
JP2004506636A (ja) | 2004-03-04 |
US6844435B2 (en) | 2005-01-18 |
CA2417635A1 (en) | 2002-02-21 |
EP1309596A2 (de) | 2003-05-14 |
DE60132702T2 (de) | 2009-03-19 |
MXPA03001306A (es) | 2003-10-15 |
WO2002014319A3 (en) | 2002-08-01 |
US20030207902A1 (en) | 2003-11-06 |
US6489328B2 (en) | 2002-12-03 |
CA2417635C (en) | 2008-02-05 |
ES2299501T3 (es) | 2008-06-01 |
ATE385498T1 (de) | 2008-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE385498T1 (de) | Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen | |
ATE277044T1 (de) | Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren | |
ATE449764T1 (de) | Cytokine, insbesondere tnf-alpha, hemmer | |
IN2014DN06567A (de) | ||
ATE532781T1 (de) | 5-(acylamino)indazol-derivate als kinase- inhibitoren | |
DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
ATE190978T1 (de) | 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung | |
MA31090B1 (fr) | Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase | |
DE602005024274D1 (de) | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine | |
MXPA04004301A (es) | Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa. | |
PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
MEP3808A (xx) | Derivati pirimidinil aril uree kao fgf inhibitori | |
EA200200058A1 (ru) | Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ | |
ATE474835T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
ATE240328T1 (de) | Substituierte azaoxindolederivate | |
EA200800017A1 (ru) | Алкилхинолиновые и алкилхиназолиновые модуляторы киназы | |
EA200800015A1 (ru) | Аминопиримидины в качестве модуляторов киназы | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
WO2004092144A3 (en) | Quinazoline compounds useful as p38 kinase inhibitors | |
ATE501128T1 (de) | 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion | |
ATE469142T1 (de) | Heterocyclische amid-derivate als cytokin- inhibitoren | |
ATE329909T1 (de) | 1,2,3-triazolamid-derivate als cytokininhibitoren | |
DE602006020293D1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin-kinasen nützlich sind | |
ATE246684T1 (de) | Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |